Poll: Will you be attending the 2023 virtual Angiogenesis, Exudation, and Degeneration meeting?
A poll for retina specialists: Let us know if you will be logging on for this annual Bascom Palmer Eye Institute symposium, which will be held virtually on February 10 and 11, 2023.
World Sight Day 2022: Eye care professionals share what global vision means to them
Coordinated by the International Agency for the Prevention of Blindness (IAPB), the international day of awareness is a reminder to "love your eyes."
POLL: Will you be attending ASRS?
A poll for retina specialists regarding their attendance at the 2022 American Society of Retina Specialists 40th Annual Scientific Meeting in New York City, New York. This poll is now closed.
AMD remote monitoring improves outcomes for patients, retrospective study shows
According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.
New programs available for residents at the Jules Stein Eye Institute
Dr. Stacy Pineles discusses the additional degree opportunities within the residency program at the Jules Stein Eye Institute at UCLA.
CANDELA Phase 2 results indicate benefits in high dose aflibercept for wet AMD
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
FDA grants Fast Track Designation to NGM Bio’s NGM621
NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.
VIVID/VISTA data study: Baseline factors affect DME resolution
Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.
Cleveland Eye Bank Foundation virtual symposium features research from top Ohio institutions
Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.
Using the IRIS registry to analyze ancillary testing patterns on a per patient basis
Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
Discovery links lupus and macular degeneration
Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.
ImprimisRx and EyePoint Pharmaceuticals expand commercial alliance for Dexycu
Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.
AAO 2021 reinvigorates ophthalmologists for 2022
Dr. McDonnell highlights inspiring moments from the 2021 annual meeting of the American Academy of Ophthalmology, along with a look ahead to next year’s conference in Chicago.
2022 is "Year of Children's Vision," as declared by Prevent Blindness
According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.
Reflecting on key takeaways from AAO 2021 with Peter J. McDonnell, MD
Peter J. McDonnell, MD, shares some of many highlights from this year’s annual meeting of the American Academy of Ophthalmology in New Orleans.
ARMOR study: data sheds light on antibiotic resistance in ophthalmology
At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.
EyeCon 2021 to cover hot topics: nAMD, gene therapy for retinal disease, sustained drug delivery
EyeCon co-chairs Peter J. McDonnell, MD, and Oluwatosin U. Smith, MD, discuss the virtual conference and its relevance to ophthalmologists across the country.
New sustained-release anti-VEGF formula proves safe and effective in phase 1 trials
Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.
Results from phase 2b study of AR-15512 for the treatment of dry eye
At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.
Prevent Blindness: National Center for Children’s Vision and Eye Health forges Children’s Vision Equity Alliance
The Children’s Vision Equity Alliance was created to improve access in children’s vision and eye health, working to advance equity in children’s vision and eye health through education, policies and partnerships.
New quality measures dashboard from Verana Health unveiled at AAO
Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.
Wearable diagnostic platform addresses gaps in vision care
Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.
Universal face masking during anti-VEGF injections reduces endophthalmitis incidence
Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.
Presbyopia-correcting drops and their potential for frustrated patients
VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.
DME: Changes to central subfield thickness linked to worse visual outcomes
Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."
ImprimisRx President John Saharek discusses 3 new products in the pipeline
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
Utilizing Widefield SS-OCTA to evaluate diabetic retinopathy severity
John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.
COED trial: Combination steroid and anti-VEGF therapy in treatment of diabetic macular edema
Ash Abbey, MD, discusses the COED trial, testing the efficacy of combining steroid and anti-VEGF therapy in patients with diabetic macular edema.
Poll results: Are you planning to attend the American Academy of Ophthalmology Meeting?
Results from our recent poll regarding AAO 2021 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in-person.
KESTREL & KITE: Reports on brolucizumab in treatment of DME
At ASRS, David Brown, MD, reported positive results at the head-to-head endpoints of KESTREL and KITE, but with continuing concerns about inflammation.
2 Clarke Drive Cranbury, NJ 08512